EO decisions and CED recommendations (English, CSV)
EO decisions and CED recommendations: English CSV file you can open as a table, filter, chart and export up to 10,000 rows. From Government of Ontario, updated Jul 2026.
- Format
- CSV
- Access
- Table on demand (prepared when opened)
- Publisher-reported update
- 2026-07-08
Information on drug funding decisions based on Executive Officer (EO) decisions and Committee to Evaluate Drugs (CED) recommendations. This information is intended for medical professionals and drug manufacturers.
Data overview
- Formats
- CSV
- File languages
- English
- Available actions
- Explore table (prepared automatically) · Access original file
Sample rows
The first 10 rows, as CanQuery read them from the start of the publisher's file on 2026-11-01.
| Generic Name | Brand Name | Strength (Format) | Manufacturer | Reason for Use | CED Recommendation | Date Reviewed | Funding Status* (Effective Date) |
|---|---|---|---|---|---|---|---|
| dalteparin sodium injection | Fragmin | 3500 IU/0.28 mL (pre-filled syringe) | Pfizer Canada Inc. | Anticoagulant | Recommended for funding | 13-Jan-16 | LU (March 30, 2016) |
| riociguat | Adempas | 0.5 mg, 1 mg , 1.5 mg , 2 mg, 2.5 mg | Bayer Inc. | Treatment of pulmonary arterial hypertension (PAH, WHO Group 1), as monotherapy or in combination with endothelin receptor antagonists, in adult patients (≥18 years of age) with WHO Functional Class … | Not recommended for funding | 13-Jan-16 | Not funded |
| lisdexamfetamine dimesylate | Vyvanse | 10 mg | Shire Pharma Canada ULC | • Attention Deficit Hyperactivity Disorder (ADHD). • Moderate to Severe Binge Eating Disorder (BED) in adults | Recommended for funding | 13-Jan-16 | GB (March 30, 2016) |
| apremilast | Otezla | 10 mg ,20 mg ,30 mg (starter pack kit) 30 mg | Celgene Inc. | Psoriatic arthritis | Not recommended for funding | 13-Jan-16 | Not funded |
| adalimumab | Humira | 40mg/0.8 mL (subcutaneous solution) | AbbVie Corporation | Weekly dosing for the treatment of Crohn's disease. | Not recommended for funding | 13-Jan-16 | Not funded |
| peginterferon beta- 1a | Plegridy | 63 mcg/0.5 mL, 94 mcg/0.5 mL, 125 mcg/0.5 mL | Biogen Canada Inc. | Treatment of relapsing remitting multiple sclerosis (RRMS) for adult patients to reduce the frequency of clinical exacerbations and to slow the progression of disability. | Not recommended for funding | 13-Jan-16 | EAP (March 13, 2017) |
| floxetine HCl | Fluoxetine | 20 mg | Sanis Health Inc. | Antidepressant | Recommended for funding | 13-Jan-16 | GB (March 20, 2016) |
| tiotropium bromide monohydrate & olodaterol hydrochloride | Inspiolto Respimat | 2.5 mcg & 2.5 mcg per actuation | Boehringer Ingelheim Canada Inc. | Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. | Recommended for funding | 13-Jan-16 | LU (March 30, 2016) |
| denosumab | Prolia | 60 mg/mL | Amgen Canada Inc. | Osteoporosis for men at high risk for fracture | Not recommended for funding | 13-Jan-16 | LU (February 29, 2012) |